Non-arteritic ischemic optic neuropathy and supplemental nitric oxide usage

por Hu, Jimmy Yan, Katz, Barrett
Publicado 2018

FRI546 VRDN-001, A Full Antagonist Antibody To IGF-1 Receptor In Development For Thyroid Eye Disease (TED): Pharmacodynamic Responses In Healthy Volunteers And Patients With Active...

por Foster, Kelly, Dickinson, Brent A, Summerfelt, Rochelle M, She, Angela, Bedian, Vahe, Katz, Barrett
Publicado 2023

FRI545 Durability Of Treatment Response With VRDN-001, A Full Antagonist Antibody To IGF-1 Receptor, In Patients With Thyroid Eye Disease (TED): Phase 1/2 Clinical Study

por Douglas, Raymond, Ugradar, Shoaib, Cockerham, Kimberley, Eric Turbin, Roger, Tang, Rosa, Nijhawan, Navdeep, O’Shaughnessy, Denis J, Summerfelt, Rochelle M, She, Angela, Katz, Barrett
Publicado 2023

Gene Therapies for the Treatment of Leber Hereditary Optic Neuropathy

por Sahel, José-Alain, Newman, Nancy J., Yu-Wai-Man, Patrick, Vignal-Clermont, Catherine, Carelli, Valerio, Biousse, Valérie, Moster, Mark L., Sergott, Robert, Klopstock, Thomas, Sadun, Alfredo A., Blouin, Laure, Katz, Barrett, Taiel, Magali
Publicado 2021

Cross-Sectional Analysis of Baseline Visual Parameters in Subjects Recruited Into the RESCUE and REVERSE ND4-LHON Gene Therapy Studies

por Moster, Mark L., Sergott, Robert C., Newman, Nancy J., Yu-Wai-Man, Patrick, Carelli, Valerio, Bryan, Molly Scannell, Smits, Gerard, Biousse, Valérie, Vignal-Clermont, Catherine, Klopstock, Thomas, Sadun, Alfredo A., DeBusk, Adam A., Carbonelli, Michele, Hage, Rabih, Priglinger, Siegfried, Karanjia, Rustum, Blouin, Laure, Taiel, Magali, Katz, Barrett, Sahel, José Alain
Publicado 2021